| A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread (NCT05431777) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-07-19 |
| Pembrolizumab in Muscle-invasive Bladder Cancer (NCT05406713) | Matthew Galsky | 2022-07-13 |
| Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies. (NCT06321640) | European Institute of Oncology | 2022-07-08 |
| A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma (NCT05302284) | RemeGen Co., Ltd. | 2022-06-14 |
| Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer (NCT05239624) | Memorial Sloan Kettering Cancer Center | 2022-06-02 |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 (NCT04879329) | Seagen, a wholly owned subsidiary of Pfizer | 2022-05-03 |
| Urothelial Tumor Risk Genes Detection With Genetron Uro V1 and LC-WGS (NCT04994197) | Ruijin Hospital | 2022-04-01 |
| A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations (NCT05242822) | Kinnate Biopharma | 2022-03-29 |
| Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer (NCT05226117) | IRCCS San Raffaele | 2022-03-23 |
| Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (NCT05200988) | The Netherlands Cancer Institute | 2022-03-14 |
| A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China (NCT05337189) | Creative Biosciences (Guangzhou) Co., Ltd. | 2022-03-09 |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO (NCT05078047) | UNICANCER | 2022-03-08 |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (NCT05243550) | UroGen Pharma Ltd. | 2022-03-01 |
| A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (NCT05234606) | Silverback Therapeutics | 2022-03-01 |
| Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma (NCT05107427) | 4D pharma plc | 2022-03-01 |
| ARON-2 Study-Multicentric International Retrospective Study (NCT05290038) | Matteo Santoni | 2022-02-17 |
| An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma (NCT04586244) | Incyte Corporation | 2022-01-14 |
| RTX-224 Monotherapy in Patients With Solid Tumors (NCT05219578) | Rubius Therapeutics | 2022-01-12 |
| Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC (NCT06120374) | Peking University First Hospital | 2022-01-01 |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) (NCT05136898) | UroGen Pharma Ltd. | 2021-11-30 |
| Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib (NCT05052372) | xCures | 2021-11-21 |
| Bio Clinical Collection of Urothelial Carcinoma (NCT04970472) | University Hospital, Toulouse | 2021-11-16 |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma (NCT05030077) | Tianjin Medical University Second Hospital | 2021-10-01 |
| Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract (NCT04617756) | Centre Hospitalier Universitaire de Nīmes | 2021-09-29 |
| UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis. (NCT05043662) | Changhai Hospital | 2021-09-01 |
| Pre-operative Immunotherapy in Stage II-III Urothelial Cancer (NCT04871594) | The Netherlands Cancer Institute | 2021-08-23 |
| GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors (NCT04977453) | GI Innovation, Inc. | 2021-08-02 |
| A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours (NCT04969835) | Avacta Life Sciences Ltd | 2021-07-16 |
| Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population (NCT05070039) | Sohag University | 2021-07-01 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (NCT04887831) | G1 Therapeutics, Inc. | 2021-06-04 |
| A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 (NCT05086666) | Abbisko Therapeutics Co, Ltd | 2021-06-03 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (NCT04895709) | Bristol-Myers Squibb | 2021-05-27 |
| Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients (NCT05046665) | South Metropolitan Health Service | 2021-05-14 |
| Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors (NCT04902872) | Cybrexa Therapeutics | 2021-05-03 |
| Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy (NCT04892849) | University of Erlangen-Nürnberg Medical School | 2021-04-30 |
| A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors (NCT04773951) | Shanghai Junshi Bioscience Co., Ltd. | 2021-04-12 |
| Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy (NCT04579133) | Latin American Cooperative Oncology Group | 2021-03-01 |
| A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (NCT04688931) | UroGen Pharma Ltd. | 2021-02-19 |
| A Study of ICP-192 in Patients With Advanced Solid Tumors (NCT04565275) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-02-01 |
| Multimodal Spectroscopy to Detect Urothelial Cancer in Urine (NCT04718948) | University of Florence | 2021-01-28 |
| Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer (NCT04553939) | Henan Cancer Hospital | 2021-01-04 |
| Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors (NCT04628780) | Pfizer | 2020-12-16 |
| LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors (NCT04666688) | PureTech | 2020-12-15 |
| Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic (NCT04770974) | University of Florence | 2020-12-10 |
| A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma (NCT04211012) | Jun Guo | 2020-11-30 |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy (NCT04596033) | Genocea Biosciences, Inc. | 2020-11-11 |
| GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy (NCT04601402) | Genome & Company | 2020-10-26 |
| Liquid Biospy for Urinary Cancers (NCT06116396) | IRCCS San Raffaele | 2020-09-29 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Ocellaris Pharma, Inc. | 2020-09-24 |
| A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors (NCT04452214) | Cantargia AB | 2020-09-24 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526) | OncoC4, Inc. | 2020-09-16 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors (NCT04242199) | Incyte Corporation | 2020-09-04 |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers (NCT04459273) | Jonsson Comprehensive Cancer Center | 2020-08-27 |
| Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma (NCT04341740) | University of Oklahoma | 2020-07-22 |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies (NCT04383938) | Aprea Therapeutics | 2020-06-25 |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors (NCT04344795) | Tempest Therapeutics | 2020-05-06 |
| Vasculogenic Mimicry in Urothelial Carcinoma (NCT04295967) | Assiut University | 2020-05-01 |
| Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention (NCT03517995) | H. Lee Moffitt Cancer Center and Research Institute | 2020-04-01 |
| Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma (NCT04322643) | Case Comprehensive Cancer Center | 2020-03-23 |
| Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility Study (NCT04223063) | Ross Mason | 2020-03-01 |
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (NCT04152499) | Klus Pharma Inc. | 2020-02-28 |
| 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy (NCT04018053) | Brigham and Women's Hospital | 2020-02-26 |
| Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response (NCT04146064) | University Health Network, Toronto | 2020-02-24 |
| Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (NCT04004442) | University of Oklahoma | 2020-02-17 |
| A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer (NCT04264936) | Peking University Cancer Hospital & Institute | 2020-02-15 |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (NCT04244552) | Atreca, Inc. | 2020-02-11 |
| Biological Effect of Vitamin D in Patients With Urothelial Carcinoma (NCT04197089) | Germans Trias i Pujol Hospital | 2020-02-11 |
| Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. (NCT04066595) | Johannes Gutenberg University Mainz | 2020-02-10 |
| A Multicenter Cancer Biospecimen Collection Study (NCT04510129) | Cofactor Genomics, Inc. | 2020-02-05 |
| Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma (NCT04173338) | Augusta University | 2020-01-23 |
| A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up (NCT04432909) | Changhai Hospital | 2020-01-17 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis (NCT04187872) | University of Florida | 2020-01-10 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963) | Ikena Oncology | 2019-12-18 |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (NCT04198766) | Inhibrx Biosciences, Inc | 2019-12-10 |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320) | Craig L Slingluff, Jr | 2019-11-21 |
| Efficacy and Utility of Cxbladder Tests in Hematuria Patients (NCT04943380) | Pacific Edge Limited | 2019-11-08 |
| Fear of Cancer Recurrence in Genitourinary Cancer (NCT04535921) | Ludwig-Maximilians - University of Munich | 2019-11-05 |
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy (NCT04623502) | University of Texas Southwestern Medical Center | 2019-09-30 |
| KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer (NCT03915405) | Kyowa Kirin, Inc. | 2019-09-26 |
| Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) (NCT03980041) | Infinity Pharmaceuticals, Inc. | 2019-09-25 |
| Prospective Trial for Examining Hematuria Using Computed Tomography (NCT04077359) | Oslo University Hospital | 2019-09-15 |
| STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA (NCT03988309) | Pacific Edge Limited | 2019-09-11 |
| Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy (NCT03945084) | University of Turin, Italy | 2019-08-27 |
| A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer (NCT04073602) | RemeGen Co., Ltd. | 2019-08-19 |
| A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer (NCT03735680) | OncoNano Medicine, Inc. | 2019-08-09 |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer (NCT04045613) | Basilea Pharmaceutica | 2019-08-02 |
| Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma (NCT04314245) | AnchorDx Medical Co., Ltd. | 2019-08-01 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) (NCT03992131) | pharmaand GmbH | 2019-06-28 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy (NCT04106167) | Fate Therapeutics | 2019-06-11 |
| Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography (NCT04113603) | Chang Gung Memorial Hospital | 2019-06-01 |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (NCT03869190) | Hoffmann-La Roche | 2019-06-01 |
| Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma (NCT03967977) | BeiGene | 2019-05-29 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469) | Xencor, Inc. | 2019-05-29 |
| Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) (NCT03898180) | Merck Sharp & Dohme LLC | 2019-05-06 |
| Application of UCAD for Diagnosing Urothelial Carcinoma. (NCT03998371) | Changhai Hospital | 2019-05-05 |
| A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (NCT03752398) | Xencor, Inc. | 2019-05-01 |
| Improve Checkpoint-blockade Response in Advanced Urothelial Cancer (NCT03871036) | The Netherlands Cancer Institute | 2019-05-01 |
| Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma (NCT04047693) | Pusan National University Yangsan Hospital | 2019-05-01 |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma (NCT03636256) | NanOlogy, LLC | 2019-04-02 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618) | Shattuck Labs, Inc. | 2019-03-26 |